| Research Topics (Medicine) | ||||
| 2019 novel coronavirus | Clinical feature | Glucocorticoid | Mental health | Real time reverse transcription polymerase chain reaction |
| Acetylsalicylic acid | Clinical laboratory techniques | Glucose | Mental stress | Remdesivir |
| Acute kidney failure | Clinical outcome | Government | Metabolic syndrome x | Respiration |
| Adolescent | Clinical trial | Guidelines | Metabolism | Respiratory failure |
| Adult | Cohort analysis | Headache | Methylprednisolone | Retrospective studies |
| Adult respiratory distress syndrome | Colorectal cancer | Health care personnel | Middle aged | Retrospective study |
| Age | Combination drug therapy | Health care policy | Middle east respiratory syndrome coronavirus | Reverse transcription polymerase chain reaction |
| Age distribution | Comorbidity | Health care quality | Monoclonal antibody | Review |
| Age factors | Comparative study | Health disparity | Monotherapy | Ribavirin |
| Aged | Complication | Health survey | Mortality | Risk assessment |
| Aging | Computer assisted tomography | Heart arrest | Mortality rate | Risk factors |
| Aha scientific statements | Constipation | Heart diseases | Multicenter study | Risk reduction |
| Alanine aminotransferase | Controlled study | Heart failure | Multiple organ failure | Sars coronavirus |
| Alcohol consumption | Coronary artery disease | Heart infarction | Myalgia | Sars virus |
| American heart association | Coronavirinae | Heart injury | Nausea | Sars-cov-2 |
| Anemia | Coronavirus | High risk population | Neoplasms | Sars-related coronavirus |
| Angiotensin converting enzyme 2 | Coronavirus disease 2019 | Hospital admission | Neutropenia | Secondary infection |
| Angiotensin receptor antagonist | Coronavirus infections | Hospital discharge | Newborn | Secondary prevention |
| Animals | Corticosteroid | Hospital mortality | Non insulin dependent diabetes mellitus | Sepsis |
| Antibiotic agent | Coughing | Hospital patient | Non small cell lung cancer | Severe acute respiratory syndrome |
| Antibodies | Covid-19 | Hospitalization | Nonhuman | Severe acute respiratory syndrome coronavirus 2 |
| Anticoagulant agent | Creatinine | Human cell | Note | Sex difference |
| Anticoagulant therapy | Critical illness | Human tissue | Nuclear magnetic resonance imaging | Sex distribution |
| Antihypertensive agent | Critically ill patient | Humans | Obesity | Sex ratio |
| Antineoplastic agent | D dimer | Hydroxychloroquine | Observational study | Shock |
| Antineoplastic combined chemotherapy protocols | Decreased appetite | Hydroxymethylglutaryl coenzyme a reductase inhibitor | Oseltamivir | Side effect |
| Antiviral agents | Demography | Hypertension | Outcome assessment | Smoking |
| Antivirus agent | Depression | Hypothyroidism | Overall survival | Sore throat |
| Anxiety | Diabetes mellitus | Immune response | Oxygen | Statistics and numerical data |
| Anxiety disorder | Diagnostic imaging | Immunoglobulin | Oxygen therapy | Stroke |
| Artificial ventilation | Diarrhea | Immunology | Pandemics | Survival analysis |
| Aspartate aminotransferase | Diet | Incidence | Pathogenesis | Survival rate |
| Asthenia | Dipeptidyl carboxypeptidase inhibitor | Incubation time | Pathogenicity | Symptom |
| Asymptomatic infection | Disease association | Infant | Pathology | Systematic review |
| Atezolizumab | Disease course | Infection control | Pathophysiology | Thorax radiography |
| Atrial fibrillation | Disease management | Infection prevention | Patient care | Throat culture |
| Betacoronavirus | Disease outbreaks | Infection risk | Percutaneous coronary intervention | Thrombocytopenia |
| Biological marker | Disease severity | Inflammation | Peripheral occlusive artery disease | Time factors |
| Blood | Disease surveillance | Information processing | Phase 3 clinical trial | Tocilizumab |
| Blood pressure | Disease transmission | Intensive care units | Phylogeny | Tomography |
| Body weight loss | Double blind procedure | Intention to treat analysis | Physical activity | Travel |
| Brain ischemia | Double-blind method | International cooperation | Physiology | Treatment duration |
| Breast cancer | Drug effect | Ischemic heart disease | Placebo | Treatment outcome |
| C reactive protein | Drug efficacy | Isolation and purification | Pneumonia | Treatment response |
| Cancer incidence | Drug safety | Kaplan meier method | Practice guideline | Trend study |
| Cancer mortality | Drug withdrawal | Kaplan-meier estimate | Pregnancy | Trends |
| Cancer registry | Dyspnea | Laboratory technique | Preschool child | Unclassified drug |
| Cancer statistics | Economics | Laboratory test | Prevalence | United kingdom |
| Cancer survival | Epidemic | Length of stay | Priority journal | Very elderly |
| Carcinoma | Epidemiology | Leukocyte count | Procedures | Viral load |
| Cardiology | Ethnicity | Lifestyle modification | Prognosis | Virology |
| Cardiovascular diseases | Europe | Liver cell carcinoma | Progression free survival | Virus genome |
| Cardiovascular mortality | Evidence based medicine | Liver neoplasms | Prospective study | Virus load |
| Cardiovascular risk | Extracorporeal oxygenation | Liver tumor | Prostate cancer | Virus pneumonia |
| Case fatality rate | Fatigue | Lopinavir plus ritonavir | Protein expression | Virus replication |
| Case report | Female | Lung | Psychology | Virus rna |
| Cause of death | Fever | Lung cancer | Public health | Virus transmission |
| Cerebrovascular accident | Follow up | Lymphocyte count | Quality of life | Vomiting |
| Child | Genetics | Lymphocytopenia | Quarantine | World health organization |
| Chloroquine | Genome | Major clinical study | Questionnaire | X-ray computed tomography |
| Chronic disease | Geographic distribution | Male | Radiography | Young adult |
| Chronic kidney failure | Global burden of disease | Malignant neoplasm | Randomized controlled trial | |
| Classification | Global disease burden | Medical research | Rash | |
| Clinical article | Global health | Medical society | Real time polymerase chain reaction |